Cargando…

Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer – the INNODIAG study

BACKGROUND: Personalized medicine has become a priority in breast cancer patient management. In addition to the routinely used clinicopathological characteristics, clinicians will have to face an increasing amount of data derived from tumor molecular profiling. The aims of this study were to develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Kempowsky-Hamon, Tatiana, Valle, Carine, Lacroix-Triki, Magali, Hedjazi, Lyamine, Trouilh, Lidwine, Lamarre, Sophie, Labourdette, Delphine, Roger, Laurence, Mhamdi, Loubna, Dalenc, Florence, Filleron, Thomas, Favre, Gilles, François, Jean-Marie, Le Lann, Marie-Véronique, Anton-Leberre, Véronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342216/
https://www.ncbi.nlm.nih.gov/pubmed/25888889
http://dx.doi.org/10.1186/s12920-015-0077-1
_version_ 1782359255491280896
author Kempowsky-Hamon, Tatiana
Valle, Carine
Lacroix-Triki, Magali
Hedjazi, Lyamine
Trouilh, Lidwine
Lamarre, Sophie
Labourdette, Delphine
Roger, Laurence
Mhamdi, Loubna
Dalenc, Florence
Filleron, Thomas
Favre, Gilles
François, Jean-Marie
Le Lann, Marie-Véronique
Anton-Leberre, Véronique
author_facet Kempowsky-Hamon, Tatiana
Valle, Carine
Lacroix-Triki, Magali
Hedjazi, Lyamine
Trouilh, Lidwine
Lamarre, Sophie
Labourdette, Delphine
Roger, Laurence
Mhamdi, Loubna
Dalenc, Florence
Filleron, Thomas
Favre, Gilles
François, Jean-Marie
Le Lann, Marie-Véronique
Anton-Leberre, Véronique
author_sort Kempowsky-Hamon, Tatiana
collection PubMed
description BACKGROUND: Personalized medicine has become a priority in breast cancer patient management. In addition to the routinely used clinicopathological characteristics, clinicians will have to face an increasing amount of data derived from tumor molecular profiling. The aims of this study were to develop a new gene selection method based on a fuzzy logic selection and classification algorithm, and to validate the gene signatures obtained on breast cancer patient cohorts. METHODS: We analyzed data from four published gene expression datasets for breast carcinomas. We identified the best discriminating genes by comparing molecular expression profiles between histologic grade 1 and 3 tumors for each of the training datasets. The most pertinent probes were selected and used to define fuzzy molecular grade 1-like (good prognosis) and fuzzy molecular grade 3-like (poor prognosis) profiles. To evaluate the prognostic performance of the fuzzy grade signatures in breast cancer tumors, a Kaplan-Meier analysis was conducted to compare the relapse-free survival deduced from histologic grade and fuzzy molecular grade classification. RESULTS: We applied the fuzzy logic selection on breast cancer databases and obtained four new gene signatures. Analysis in the training public sets showed good performance of these gene signatures for grade (sensitivity from 90% to 95%, specificity 67% to 93%). To validate these gene signatures, we designed probes on custom microarrays and tested them on 150 invasive breast carcinomas. Good performance was obtained with an error rate of less than 10%. For one gene signature, among 74 histologic grade 3 and 18 grade 1 tumors, 88 cases (96%) were correctly assigned. Interestingly histologic grade 2 tumors (n = 58) were split in these two molecular grade categories. CONCLUSION: We confirmed the use of fuzzy logic selection as a new tool to identify gene signatures with good reliability and increased classification power. This method based on artificial intelligence algorithms was successfully applied to breast cancers molecular grade classification allowing histologic grade 2 classification into grade 1 and grade 2 like to improve patients prognosis. It opens the way to further development for identification of new biomarker combinations in other applications such as prediction of treatment response. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12920-015-0077-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4342216
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43422162015-02-27 Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer – the INNODIAG study Kempowsky-Hamon, Tatiana Valle, Carine Lacroix-Triki, Magali Hedjazi, Lyamine Trouilh, Lidwine Lamarre, Sophie Labourdette, Delphine Roger, Laurence Mhamdi, Loubna Dalenc, Florence Filleron, Thomas Favre, Gilles François, Jean-Marie Le Lann, Marie-Véronique Anton-Leberre, Véronique BMC Med Genomics Research Article BACKGROUND: Personalized medicine has become a priority in breast cancer patient management. In addition to the routinely used clinicopathological characteristics, clinicians will have to face an increasing amount of data derived from tumor molecular profiling. The aims of this study were to develop a new gene selection method based on a fuzzy logic selection and classification algorithm, and to validate the gene signatures obtained on breast cancer patient cohorts. METHODS: We analyzed data from four published gene expression datasets for breast carcinomas. We identified the best discriminating genes by comparing molecular expression profiles between histologic grade 1 and 3 tumors for each of the training datasets. The most pertinent probes were selected and used to define fuzzy molecular grade 1-like (good prognosis) and fuzzy molecular grade 3-like (poor prognosis) profiles. To evaluate the prognostic performance of the fuzzy grade signatures in breast cancer tumors, a Kaplan-Meier analysis was conducted to compare the relapse-free survival deduced from histologic grade and fuzzy molecular grade classification. RESULTS: We applied the fuzzy logic selection on breast cancer databases and obtained four new gene signatures. Analysis in the training public sets showed good performance of these gene signatures for grade (sensitivity from 90% to 95%, specificity 67% to 93%). To validate these gene signatures, we designed probes on custom microarrays and tested them on 150 invasive breast carcinomas. Good performance was obtained with an error rate of less than 10%. For one gene signature, among 74 histologic grade 3 and 18 grade 1 tumors, 88 cases (96%) were correctly assigned. Interestingly histologic grade 2 tumors (n = 58) were split in these two molecular grade categories. CONCLUSION: We confirmed the use of fuzzy logic selection as a new tool to identify gene signatures with good reliability and increased classification power. This method based on artificial intelligence algorithms was successfully applied to breast cancers molecular grade classification allowing histologic grade 2 classification into grade 1 and grade 2 like to improve patients prognosis. It opens the way to further development for identification of new biomarker combinations in other applications such as prediction of treatment response. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12920-015-0077-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-02-07 /pmc/articles/PMC4342216/ /pubmed/25888889 http://dx.doi.org/10.1186/s12920-015-0077-1 Text en © Kempowsky-Hamon et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kempowsky-Hamon, Tatiana
Valle, Carine
Lacroix-Triki, Magali
Hedjazi, Lyamine
Trouilh, Lidwine
Lamarre, Sophie
Labourdette, Delphine
Roger, Laurence
Mhamdi, Loubna
Dalenc, Florence
Filleron, Thomas
Favre, Gilles
François, Jean-Marie
Le Lann, Marie-Véronique
Anton-Leberre, Véronique
Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer – the INNODIAG study
title Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer – the INNODIAG study
title_full Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer – the INNODIAG study
title_fullStr Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer – the INNODIAG study
title_full_unstemmed Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer – the INNODIAG study
title_short Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer – the INNODIAG study
title_sort fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer – the innodiag study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342216/
https://www.ncbi.nlm.nih.gov/pubmed/25888889
http://dx.doi.org/10.1186/s12920-015-0077-1
work_keys_str_mv AT kempowskyhamontatiana fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT vallecarine fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT lacroixtrikimagali fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT hedjazilyamine fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT trouilhlidwine fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT lamarresophie fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT labourdettedelphine fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT rogerlaurence fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT mhamdiloubna fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT dalencflorence fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT filleronthomas fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT favregilles fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT francoisjeanmarie fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT lelannmarieveronique fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy
AT antonleberreveronique fuzzylogicselectionasanewreliabletooltoidentifymoleculargradesignaturesinbreastcancertheinnodiagstudy